Cns Pharmaceuticals Inc (CNSP)

Apr 11, 2025

CNS Pharma Stock Price, Quotes and Forecasts | NASDAQ:CNSP - Benzinga

Apr 11, 2025

Apr 09, 2025

CNS Pharmaceuticals Advances TPI 287 for Glioblastoma - TipRanks

Apr 09, 2025

Apr 06, 2025

CNS Pharmaceuticals to Report Fourth Quarter 2019 Financial Results on March 12, 2020 - BioSpace

Apr 06, 2025

Apr 05, 2025

Financial Survey: KalVista Pharmaceuticals (NASDAQ:KALV) and CNS Pharmaceuticals (NASDAQ:CNSP) - Defense World

Apr 05, 2025

Apr 02, 2025

CNS Pharmaceuticals reports FY24 EPS ($38.87) vs. ($12,509.11) last year - Yahoo Finance

Apr 02, 2025

Apr 01, 2025

CNS Pharmaceuticals Reports Full Year 2024 Financial Results - Yahoo Finance

Apr 01, 2025

Apr 01, 2025

CNS Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Apr 01, 2025

Apr 01, 2025

CNS Pharmaceuticals (NASDAQ: CNSP) Advances TPI 287 for GBM, Ends 2024 with Strong Cash Position - The Globe and Mail

Apr 01, 2025

Mar 26, 2025

CNS Pharmaceuticals (NASDAQ:CNSP) Receives Hold Rating from Maxim Group - Defense World

Mar 26, 2025

Mar 26, 2025

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP): When Will It Breakeven? - Yahoo Finance

Mar 26, 2025

Mar 26, 2025

Market Sentiment Around Loss-Making CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) - simplywall.st

Mar 26, 2025

Mar 25, 2025

CNSP stock touches 52-week low at $1.49 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 25, 2025

Mar 25, 2025

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Mar 25, 2025

Mar 25, 2025

CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects - AInvest

Mar 25, 2025

Mar 25, 2025

Nasdaq Gains 50 Points; US New Home Sales Rise In February - Benzinga

Mar 25, 2025

Mar 25, 2025

CNSP stock touches 52-week low at $1.49 amid sharp annual decline - Investing.com

Mar 25, 2025

Mar 25, 2025

CNS Pharmaceuticals shares tumble after clinical trial results By Investing.com - Investing.com South Africa

Mar 25, 2025

Mar 25, 2025

CNS Pharmaceuticals shares tumble after clinical trial results - Investing.com India

Mar 25, 2025

Mar 25, 2025

CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme - Yahoo Finance

Mar 25, 2025

Mar 20, 2025

CNS Pharmaceuticals expands stock sale agreement to $43.5 million - Investing.com

Mar 20, 2025

Mar 20, 2025

CNS Pharmaceuticals expands stock sale agreement to $43.5 million By Investing.com - Investing.com UK

Mar 20, 2025

Mar 20, 2025

The International Society for CNS Drug Development (ISCDD) Honors Sharon Mates, PhD, and Steven Paul, MD with Prestigious Leadership Award at 23rd Annual Meeting - Yahoo Finance

Mar 20, 2025

Mar 20, 2025

Plus Therapeutics Scores FDA Recognition for REYOBIQ Cancer DrugMajor Milestone for CNS Treatment - Stock Titan

Mar 20, 2025

Mar 17, 2025

Central Nervous System (CNS) Therapeutics Market to Reach USD - openPR

Mar 17, 2025

Mar 13, 2025

Houston’s Life Sciences Scene Continues Boosting Its Reputation - BioSpace

Mar 13, 2025

Mar 12, 2025

Xenon Pharmaceuticals Reveals Latest Progress on Revolutionary CNS Drug Development - Stock Titan

Mar 12, 2025

Mar 11, 2025

Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum - Business Wire

Mar 11, 2025

Mar 07, 2025

Cns Pharmaceuticals Inc to Host Earnings Call - ACCESS Newswire

Mar 07, 2025

Mar 06, 2025

Trimtech closes seed fund round to advance CNS therapeutics pipeline - Pharmaceutical Technology

Mar 06, 2025

Mar 03, 2025

CNSP stock touches 52-week low at $2.2 amid sharp annual decline - Investing.com Australia

Mar 03, 2025

Mar 03, 2025

CNSP stock touches 52-week low at $2.2 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 03, 2025

Feb 26, 2025

CNS Pharmaceuticals jumps on current cash position update - MSN

Feb 26, 2025

Feb 26, 2025

CNS Pharmaceuticals secures NASDAQ listing and funding into 2026 By Investing.com - Investing.com South Africa

Feb 26, 2025

Feb 26, 2025

CNS Pharmaceuticals reports cash position of $14M as of February 26 - TipRanks

Feb 26, 2025

Feb 26, 2025

CNS Pharmaceuticals secures NASDAQ listing and funding into 2026 - Investing.com

Feb 26, 2025

Feb 26, 2025

Can CNS Pharmaceuticals' $14M War Chest Deliver on Its Promising Brain Cancer Treatment? - StockTitan

Feb 26, 2025

Feb 26, 2025

CNS Pharmaceuticals (NASDAQ: CNSP) Updates Cash Position, Nasdaq Compliance, and Clinical Progress - The Globe and Mail

Feb 26, 2025

Feb 25, 2025

CNS Pharmaceuticals to implement 1-for-50 reverse stock split - MSN

Feb 25, 2025

Feb 21, 2025

CNS Pharmaceuticals (NASDAQ: CNSP) CEO to Present at European Life Sciences CEO Forum - Barchart

Feb 21, 2025

Feb 20, 2025

CNS Pharmaceuticals (NASDAQ: CNSP) Highlights 2025 Outlook at Virtual Investor Conference - The Globe and Mail

Feb 20, 2025

Feb 20, 2025

CNS Pharmaceuticals Advances Berubicin and TPI 287 Projects - MSN

Feb 20, 2025

Feb 20, 2025

CNSPCNS Pharmaceuticals Latest Stock News & Market Updates - Stock Titan

Feb 20, 2025

Feb 20, 2025

CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum - ACCESS Newswire

Feb 20, 2025

Feb 20, 2025

Can CNS Pharmaceuticals' Brain Cancer Breakthrough Change Treatment Landscape? CEO Presents Next Week - Stock Titan

Feb 20, 2025

Feb 19, 2025

CNS Pharmaceuticals enacts 1-for-50 reverse stock split - Investing.com

Feb 19, 2025

Feb 19, 2025

CNSP stock touches 52-week low at $0.08 amid sharp annual decline - Investing.com India

Feb 19, 2025

Feb 19, 2025

CNS Pharmaceuticals to Implement 1-for-50 Reverse Stock Split; Shares Down -February 19, 2025 at 10:28 am EST - Marketscreener.com

Feb 19, 2025

Feb 19, 2025

Can CNS Pharmaceuticals' 5 Key Growth Drivers Transform Brain Cancer Treatment? CEO Reveals 2025 Roadmap - StockTitan

Feb 19, 2025

Feb 19, 2025

Can This Drastic 1:50 Reverse Split Save CNS Pharmaceuticals' Nasdaq Listing? - StockTitan

Feb 19, 2025

Feb 18, 2025

CNS Pharmaceuticals to present at Glioblastoma Drug Development Summit - TipRanks

Feb 18, 2025